These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32824655)

  • 1. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
    Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
    Bocanegra A; Fernandez-Hinojal G; Zuazo-Ibarra M; Arasanz H; Garcia-Granda MJ; Hernandez C; Ibañez M; Hernandez-Marin B; Martinez-Aguillo M; Lecumberri MJ; Fernandez de Lascoiti A; Teijeira L; Morilla I; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
    Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W
    Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
    Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
    IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
    Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
    Front Immunol; 2019; 10():1337. PubMed ID: 31258527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
    Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
    Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
    Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
    Del Re M; van Schaik RHN; Fogli S; Mathijssen RHJ; Cucchiara F; Capuano A; Scavone C; Jenster GW; Danesi R
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188463. PubMed ID: 33137405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
    Germanà E; Pepe L; Pizzimenti C; Ballato M; Pierconti F; Tuccari G; Ieni A; Giuffrè G; Fadda G; Fiorentino V; Martini M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
    Ni JM; Ni AP
    Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 18. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
    García-Aranda M; Redondo M
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31075880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.